JP2022522185A5 - - Google Patents

Info

Publication number
JP2022522185A5
JP2022522185A5 JP2021550074A JP2021550074A JP2022522185A5 JP 2022522185 A5 JP2022522185 A5 JP 2022522185A5 JP 2021550074 A JP2021550074 A JP 2021550074A JP 2021550074 A JP2021550074 A JP 2021550074A JP 2022522185 A5 JP2022522185 A5 JP 2022522185A5
Authority
JP
Japan
Prior art keywords
eomes
cells
treatment
subject
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021550074A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522185A (ja
JP7520389B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2020/050172 external-priority patent/WO2020172712A1/en
Publication of JP2022522185A publication Critical patent/JP2022522185A/ja
Publication of JP2022522185A5 publication Critical patent/JP2022522185A5/ja
Application granted granted Critical
Publication of JP7520389B2 publication Critical patent/JP7520389B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021550074A 2019-02-27 2020-02-27 Ｔ細胞機能を評価して治療法に対する応答を予測するための方法および薬剤 Active JP7520389B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019900628A AU2019900628A0 (en) 2019-02-27 Methods and agents for assessing t-cell function and predicting response to therapy
AU2019900628 2019-02-27
PCT/AU2020/050172 WO2020172712A1 (en) 2019-02-27 2020-02-27 Methods and agents for assessing t-cell function and predicting response to therapy

Publications (3)

Publication Number Publication Date
JP2022522185A JP2022522185A (ja) 2022-04-14
JP2022522185A5 true JP2022522185A5 (https=) 2023-02-27
JP7520389B2 JP7520389B2 (ja) 2024-07-23

Family

ID=72238249

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021550074A Active JP7520389B2 (ja) 2019-02-27 2020-02-27 Ｔ細胞機能を評価して治療法に対する応答を予測するための方法および薬剤

Country Status (8)

Country Link
US (1) US20220146495A1 (https=)
EP (1) EP3931565A4 (https=)
JP (1) JP7520389B2 (https=)
CN (1) CN113677994B (https=)
AU (1) AU2020227319A1 (https=)
CA (1) CA3131268A1 (https=)
SG (1) SG11202108707WA (https=)
WO (1) WO2020172712A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022174129A1 (en) * 2021-02-15 2022-08-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Recombinant eomes restores anti-cancer activity of immune cells
KR102534243B1 (ko) * 2022-12-05 2023-05-31 넥스탭 주식회사 Eomes 단백질을 표적으로 하는 인터페론-γ 조절 물질의 확인방법 및 이 물질을 포함하는 의약

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DE69428764T2 (de) 1993-12-24 2002-06-20 Merck Patent Gmbh Immunokonjugate
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
SI9620103A (sl) 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
AR007857A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios uso en medicina ycomposiciones farmaceuticas que los contienen.
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998050038A1 (en) 1997-05-06 1998-11-12 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
BR9814116A (pt) 1997-11-06 2000-10-03 American Cyanamid Co Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico
EA003786B1 (ru) 1998-11-19 2003-10-30 Варнер Ламберт Компани N-[4-(3-хлор-4-фторфениламино)-7-(3-морфолин-4-илпропокси)хиназолин-6-ил]акриламид - необратимый ингибитор тирозинкиназ
WO2001031580A2 (en) 1999-10-27 2001-05-03 Biowulf Technologies, Llc Methods and devices for identifying patterns in biological systems
US6925389B2 (en) 2000-07-18 2005-08-02 Correlogic Systems, Inc., Process for discriminating between biological states based on hidden patterns from biological data
AU2002245043B2 (en) 2000-11-16 2006-10-26 Bio-Rad Laboratories, Inc. Method for analyzing mass spectra
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
JP2011160711A (ja) * 2010-02-09 2011-08-25 Keio Gijuku 特定の遺伝子のメチル化の頻度を、婦人科がんのバイオマーカーとして使用する方法
GB201316347D0 (en) * 2013-09-13 2013-10-30 Cancer Rec Tech Ltd Biological fluid filtration assembly
US10927410B2 (en) * 2014-10-17 2021-02-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of T-cell exhaustion using CD39 biomarkers and modulators
WO2016118852A1 (en) * 2015-01-23 2016-07-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of eomesodermin to determine risk of allograft rejection
EP3277689B1 (en) * 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
CN106047818A (zh) * 2016-08-05 2016-10-26 武汉赛云博生物科技有限公司 癌胚抗原特异性tcr基因修饰的t细胞及其抑癌用途
WO2018104909A2 (en) * 2016-12-09 2018-06-14 St. Jude Children's Research Hospital Dna methylation profiling for t-cell immunotherapy

Similar Documents

Publication Publication Date Title
Kim et al. The first-week proliferative response of peripheral blood PD-1+ CD8+ T cells predicts the response to anti-PD-1 therapy in solid tumors
Nixon et al. Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
Jiang et al. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer
Li et al. Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer
Takada et al. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy
EP2561363B1 (en) Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
Liu et al. Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities
ES2703714T3 (es) Métodos de identificación, evaluación, prevención y terapia de enfermedades pulmonares y kits de los mismos, incluida la identificación, evaluación, prevención y terapia de enfermedades en base al género
JP2018509934A5 (https=)
McAndrew et al. Effects of systemic inflammation on relapse in early breast cancer
US20140220006A1 (en) Lung cancer biomarkers
Dulmage et al. The biomarker landscape in mycosis fungoides and Sézary syndrome
Zhao et al. Serum IL‐5 and IFN‐γ Are Novel Predictive Biomarkers for Anti‐PD‐1 Treatment in NSCLC and GC Patients
US20210116452A1 (en) Lung cancer biomarkers
Kos et al. Evaluation of the effects of red blood cell distribution width on survival in lung cancer patients
JP2022522185A5 (https=)
CN113358872A (zh) 用于评估肿瘤免疫治疗疗效的标志物组及系统
Esposito et al. Early assessment of IL8 and PD1+ Treg predicts response and guides treatment monitoring in cemiplimab-treated cutaneous squamous cell carcinoma
Shen et al. Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens
Karayama et al. Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer
US20170205418A1 (en) Biomarkers of therapeutic responsiveness
Lee et al. M2BPGi correlated with immunological biomarkers and further stratified recurrence risk in patients with hepatocellular carcinoma
Verdonk et al. Ex vivo pembrolizumab pharmacology for personalized PD-1 inhibitor therapy reveals a critical gap between receptor occupancy and T cell functionality
Cerciello et al. Verification of a blood-based targeted proteomics signature for malignant pleural mesothelioma
EP3519813B1 (en) Monitoring cancer recurrence and progression